Exchange: NASDAQ·Updated 07:58 PM EDT
MLTX logo

MLTXMoonLake Immunotherapeutics

$19.47
$0.44
(2.21%)
Today
Closed $19.47
$0.20
(1.03%)
After Hours
EarningsAug 4
Mkt Cap$1.47B
Vol1.49M
News
all
press releases
MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa
MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa...
Yahoo! Finance: News
News Placeholder
More News
News Placeholder
Why MoonLake Immunotherapeutics Stock Wilted on Wednesday
Key PointsIt aims to raise up to $200 million in the offering...
Nasdaq News: Markets
News Placeholder
MLTX Stock Extends Pullback After Biggest Rally In Over 6 Months Following Skin Disease Trial Data — A Look At The Latest Development
The biotech firm upsized its offering to $200 million, up from the previously announced $150 million.
Stocktwits
News Placeholder
MLTX Stock Clocks Best Day In Over 6 Months — What’s Driving The Investor Optimism?
Clear Street described sonelokimab’s profile in hidradenitis suppurativa as highly competitive and one that readily supports “blockbuster potential.”
Stocktwits
News Placeholder
Why Is MoonLake Immunotherapeutics Stock Soaring Monday?
MoonLake reported durable one-year Phase 3 hidradenitis suppurativa data for sonelokimab and plans an FDA filing in September 2026.read more...
Benzinga
News Placeholder
S&P 500, Nasdaq, Dow Futures Slip After Trump Warns Iran Of Fresh Strikes Over Hormuz Standoff: INTC, MLTX, SNDK, KEEL In Focus
Iran argued that Washington had failed to uphold commitments to curb hostilities in Lebanon.
Stocktwits
News Placeholder
Why Is MLTX Stock Rallying Nearly 20% Overnight?
Key upcoming catalysts include MoonLake's Investor Day on Monday, an FDA filing in September, and additional late-stage pipeline readouts later this year.
Stocktwits
News Placeholder
MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts
Moonlake’s lead drug Sonelokimab is being tested across inflammatory conditions, with the biggest near-term focus on hidradenitis suppurativa.
Stocktwits
News Placeholder
Why Did MLTX Stock Rise After-Hours Today?
Investors are awaiting multiple Phase 3 readouts in the second half of the year, including Vela, Izar and Vela-Teen trial results.
Stocktwits
News Placeholder
MoonLake Immunotherapeutics CFO Trims His Stake. Should Investors Be Concerned?
Key PointsBodenstedt sold 13,653 shares for a transaction value of ~$273,000 at around $20.02 per share on May 11, 2026...
Nasdaq News: Markets
<
1
2
...
>

Advertisement|Remove ads.